These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32995483)

  • 41. Bright future or blind alley? CAR-T cell therapy for solid tumors.
    Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
    Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors.
    Fan J; Das JK; Xiong X; Chen H; Song J
    Front Oncol; 2020; 10():574860. PubMed ID: 33489881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
    Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
    Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins.
    Qiao Y; Chen J; Wang X; Yan S; Tan J; Xia B; Chen Y; Lin K; Zou F; Liu B; He X; Zhang Y; Zhang X; Zhang H; Wu X; Lu L
    Cancer Commun (Lond); 2023 Jul; 43(7):788-807. PubMed ID: 37282786
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach.
    Entezam M; Sanaei MJ; Mirzaei Y; Mer AH; Abdollahpour-Alitappeh M; Azadegan-Dehkordi F; Bagheri N
    Life Sci; 2023 Apr; 318():121459. PubMed ID: 36720453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors.
    Chen Q; Lu L; Ma W
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30
    Hombach AA; Rappl G; Abken H
    Mol Ther; 2019 Oct; 27(10):1825-1835. PubMed ID: 31331813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
    Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells.
    Bashiri Dezfouli A; Yazdi M; Benmebarek MR; Schwab M; Michaelides S; Miccichè A; Geerts D; Stangl S; Klapproth S; Wagner E; Kobold S; Multhoff G
    Front Immunol; 2022; 13():883694. PubMed ID: 35720311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
    Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
    J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
    Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
    Front Immunol; 2017; 8():1850. PubMed ID: 29312333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.
    Ghanem MH; Bolivar-Wagers S; Dey B; Hajduczki A; Vargas-Inchaustegui DA; Danielson DT; Bundoc V; Liu L; Berger EA
    Cytotherapy; 2018 Mar; 20(3):407-419. PubMed ID: 29306566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
    Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
    Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 59. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors
    Koneru M; Purdon TJ; Spriggs D; Koneru S; Brentjens RJ
    Oncoimmunology; 2015 Mar; 4(3):e994446. PubMed ID: 25949921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.